|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings suggest that CDK6 could be a therapeutic target for the development of future treatments for NPM-ALK<sup>+</sup> anaplastic large-cell lymphoma.
|
30262555 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK<sup>+</sup> anaplastic large cell lymphoma.
|
29086626 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma.
|
29488330 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The anaplastic lymphoma kinase (ALK) gene was initially identified as a fusion partner of the nucleophosmin gene in anaplastic large-cell lymphoma with t(2;5)(p23;q35) translocation, and then described with different genetic abnormalities in a number of tumors.
|
28756644 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
|
27694894 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To this end, immunocomplexes of FLAG-tagged PKM2 were isolated from NPM-ALK-positive ALCL (anaplastic large cell lymphoma) cells and subjected to liquid chromatography tandem mass spectrometry (LC-MS/MS) which led to the identification of polypyrimidine tract-binding protein (PTBP1) as a novel interactor of PKM2.
|
28414323 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
|
27414060 |
2016 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
|
25874976 |
2015 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As proof-of-principle, we apply hiBA-FISH to detect with high sensitivity and specificity rare chromosome breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM1 and ALK.
|
26313373 |
2015 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We assessed ALK genomic status in tumour tissue and used quantitative RT-PCR to measure NPM-ALK fusion transcript in bone marrow and blood samples of patients with anaplastic large-cell lymphoma.
|
23598171 |
2013 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK is rendered oncogenic as a result of its fusion to NPM1 in anaplastic large cell lymphoma, to TPM3 or TPM4 in inflammatory myofibroblastic tumor, to EML4 in non-small cell lung carcinoma, and to VCL in renal medullary carcinoma.
|
22614325 |
2012 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
|
22042699 |
2011 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The anaplastic lymphoma kinase (ALK), a transmembrane RTK, originally identified in the nucleophosmin (NPM)-ALK chimera of anaplastic large cell lymphoma, has emerged as a novel tumorigenic player in several human cancers.
|
21502284 |
2011 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
|
20554525 |
2010 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation.
|
19545284 |
2009 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ALK (anaplastic lymphoma kinase) RTK was originally identified as a member of the insulin receptor subfamily of RTKs that acquires transforming capability when truncated and fused to NPM (nucleophosmin) in the t(2;5) chromosomal rearrangement associated with ALCL (anaplastic large cell lymphoma).
|
19459784 |
2009 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
|
19423729 |
2009 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
|
17416736 |
2007 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
|
17537995 |
2007 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
|
16825495 |
2006 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NPM1 gene on 5q35 is translocated with the anaplastic lymphoma kinase (ALK) gene in anaplastic large cell lymphoma with t(2;5).
|
16984370 |
2006 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
|
16982741 |
2006 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor originally identified as part of the chimeric nucleophosmin-ALK protein in the t(2;5) chromosomal rearrangement associated with anaplastic large cell lymphoma.
|
15972965 |
2005 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
|
15093542 |
2004 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
|
14962911 |
2004 |